Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 2/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996112 | 1.00 | SLC15A1 (0.66) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL997986 | 1.00 | SLC15A1 (0.66) | SLC15A1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL4981923 | 0.98 | SLC15A1 (0.64) | SLC15A1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL1758457 | 0.98 | SLC15A1 (0.64) | SLC15A1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL6160157 | 0.84 | LTA4H (0.61) | LTA4HLAP3 | |
| SCHEMBL5060967 | 0.82 | ALPI (0.68) | SLC15A1ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28138410 | 0.82 | SLC7A5 (0.88) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL12323250 | 0.82 | SLC7A5 (0.68) | SLC15A1ALPIPKMPTGS1XIAP | |
| SCHEMBL28110902 | 0.82 | ALPI (0.68) | SLC15A1ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL430395 | 0.81 | SLC7A5 (0.79) | SLC15A1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708740-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES | Rytek (FR) | 2006-10-11 | — | — | EP | claimed |
| WO-2005077406-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES | RYTEK (FR) | 2005-08-25 | — | — | WO | claimed |
| US-12030928-B2 | Anti-influenza B virus neuraminidase antibodies and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240091337-A1 | INFLUENZA B VIRUS MUTANTS AND USES THEREFOR | FLUGEN, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| CN-117511844-A | Non-invasive method for generating human nasopharyngeal three-and two-dimensional organoids | 免疫与感染研究中心有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4267610-A1 | COMPOSITION OF PIG POLYCLONAL ANTIBODY FOR ITS USE TO TREAT AND/OR PREVENT ANTIBODY-DEPENDENT MACROPHAGE PRO-INFLAMMATORY CYTOKINE RELEASE IN A PASSIVE ANTI-INFECTIOUS IMMUNOTHERAPY | Xenothera (FR) | 2023-11-01 | — | — | EP | disclosed |
| EP-4244378-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | Innovative Diagnostics (FR) | 2023-09-20 | — | — | EP | disclosed |
| EP-4205754-A1 | ANTIVIRAL PLANT EXTRACT COMPOSITION AND METHOD FOR PREPARING SUCH COMPOSITION | Cariel, Léon (FR) | 2023-07-05 | — | — | EP | disclosed |
| EP-4205753-A1 | ANTIVIRAL PLANT EXTRACT COMPOSITION AND METHOD FOR PREPARING SUCH COMPOSITION | Cariel, Léon (FR) | 2023-07-05 | — | — | EP | disclosed |
| US-11529409-B2 | Influenza B virus mutants and uses therefor | FLUGEN, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-0159156-A1 | Hydroxy substituted ureido amino and imino acids | E.R. Squibb & Sons, Inc. (US) | 1985-10-23 | — | — | EP | disclosed |
| EP-0154904-A1 | Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines | E.R. Squibb & Sons, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4535176-A | HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0142335-A2 | Lactam containing compounds | E.R. Squibb & Sons, Inc. (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4514391-A | HYPOTENSIVE AGENTS; ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1985-04-30 | — | — | US | disclosed |
| US-4512988-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0132304-A2 | Hydroxy substituted peptide compounds | E.R. Squibb & Sons, Inc. (US) | 1985-01-30 | — | — | EP | disclosed |
| US-4474778-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091337-A1 | INFLUENZA B VIRUS MUTANTS AND USES THEREFOR | HAVCR2, CMBL, CD81 | SLC15A1 3525/4885ALPI 3557/4885PKM 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.